Companies/US/SONO

SONOS, INC.

Last · NASDAQ$17.60-0.12 (-0.68%)close · yahoo · 16h ago
Vol 1.51M ≈ 26.52M
Market cap$2.08B118.3M sh
P/E · TTM39.1fwd 13.5 · eps 0.45
Beta1.88vs S&P 500
Div yield0.00%annual · TTM
52w range
$12.44$19.82
Volume1.5Msession

Issuer

Legal nameSONOS, INC.
HQUnited States (US)
ListingUS SONO
ISINUS83570H1086
SectorTechnology
IndustryElectronics (Consumer & Office)
SIC3651
CurrencyUSD
Entity registrysec:0001314727
CIK0001314727
LinkedIn
Employees1,404
AddressSonos, Inc. 301 Coromar Drive 93117, Santa Barbara +805 965 3001
Headline financial metrics
Revenue$1.5B
Operating income$100.4M
Net income$94.8M
Free cash flow$127.5M
Operating margin6.7%
Net margin6.4%
Return on equity23.5%
PeriodTTM 2026-06-27
Loading chart…

OpenFilings analyst

Our analyst

Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.

High-quality growth and raised guidance are offset by unresolved Librela adoption and competitive-launch risk.

Latest call · Q3 2026

Zoetis delivered a strong Q2:

revenue was $2.5 billion, up 8% organically, adjusted net income rose 10%, and management raised 2025 organic revenue-growth guidance to 6.5%-8%. The core Simparica and dermatology franchises remain resilient, but Librela fell 16% in the U.S. and the expected Q4 dermatology launch creates meaningful second-half risk; the call supports a hold rather than a fresh buy until those issues improve.

Themes
  • Q2 2025 Results
  • Simparica Trio
  • Dermatology Competition
  • Librela Adoption
  • Alternative Channels
  • Livestock Growth
+2

Near term

Q3-Q4 comparisons become difficult, with U.S. companion-animal revenue having grown 18% in Q3 2024.

A competing dermatology product is expected to launch in Q4, with promotional intensity and label scope still uncertain.

Librela third-party studies are expected to begin reading out in Q4 2025 and continue into 2026; evidence will be important for restoring veterinarian recommendations.

Tariff treatment remains unclear, although management says currently enacted and announced tariffs are embedded in guidance and manageable.

Alternative channels represented about 22% of U.S. companion-animal revenue and grew 25%-30%, but retail stocking provided a potentially temporary benefit.

Longer term

Simparica Trio remains a strong growth engine: triple-combination share in U.S. veterinary practices reached 45%, and management expects the category to double by the end of 2028.

Key dermatology grew 11% in Q2 and continues to benefit from under-treated or untreated medicalized dogs, compliance, and differentiated Apoquel Chew and Cytopoint offerings.

Management expects a major-market approval every year for the next several years, including long-acting osteoarthritis products and potential renal, oncology, and cardiology opportunities.

Livestock growth has exceeded expectations for five consecutive quarters, adding diversification beyond companion animal franchises.

Competitive moat risk remains concentrated in parasiticide and dermatology launches; management's claims of stable patient share need to be tested through the upcoming Q4 launch cycle.

Red flags

Librela declined 16% in U.S. sales and 7% globally in Q2; management acknowledged adoption and veterinarian recommendation have materially lagged expectations.

Management could not provide a timing target for Librela's return to year-over-year growth, relying instead on education and future third-party data.

International Librela growth slowed to 1%, with social-media headwinds spreading into English-speaking markets.

The raised full-year outlook still assumes launch-related competitive headwinds in the second half, and management described timing, promotional intensity, and competitor labels as uncertain.

Reported adjusted gross margin of 73.7% benefited from FX and the MFA divestiture; manufacturing-cost improvement is expected, but underlying margin progression remains partly timing-dependent.

Forward outlook

revenue

9450–9600 $million

FY 2025

official guidance

revenue growth

6.5–8 pct

FY 2025

official guidance

adjusted eps

6.3–6.4 $per share

FY 2025

official guidance

Recommendation history

OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.

Upcoming earnings

1 event
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$0.05
Est. revenue
340.3M

Earnings transcripts

12 of 58 recent

Documents

FormReporting forFiledFlags
—2026-09-30≈0
—2026-09-30≈0
—2026-09-30≈0
2026-09-252026-09-280
2026-09-012026-09-030